nach oben

Current Cardiology Reports

Erschienen in:

01.07.2017 | Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype

verfasst von: Veronika Sanin, Vanessa Pfetsch, Wolfgang Koenig

Erschienen in: Current Cardiology Reports | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This study aimed to present the current information on the genetic background of dyslipidemias and provide insights into the complex pathophysiological role of several plasma lipids/lipoproteins in the pathogenesis of atherosclerotic cardiovascular disease. Furthermore, we aim to summarize established therapies and describe the scientific rationale for the development of novel therapeutic strategies.

Recent Findings

Evidence from genetic studies suggests that besides lowering low-density lipoprotein cholesterol, pharmacological reduction of triglyceride-rich lipoproteins, or lipoprotein(a) will reduce risk for coronary heart disease.

Summary

Dyslipidemia, in particular hypercholesterolemia, is a common clinical condition and represents an important determinant of atherosclerotic vascular disease. Treatment decisions are currently guided by the causative lipid phenotype and the presence of other risk factors suggesting a very high cardiovascular risk. Therefore, the identification of lipid disorders and the optimal combination of therapeutic strategies provide an outstanding opportunity for reducing the onset and burden of cardiovascular disease.

Ramasamy I. Update on the molecular biology of dyslipidemias. Clin Chim Acta; Int J Clin Chem. 2016;454:143–85. doi:10.1016/j.cca.2015.10.033.CrossRef

Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36(9):539–50. doi:10.1093/eurheartj/eht571.PubMedCrossRef

Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53. doi:10.1093/eurheartj/ehq386.PubMedPubMedCentralCrossRef

Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161–72. doi:10.1016/j.cell.2015.01.036.PubMedPubMedCentralCrossRef

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (London, England). 1994;344(8934):1383–9.

Luscher TF. Dyslipidaemias: new mechanistic insights and the 2016 ESC guidelines. Eur Heart J. 2016;37(39):2963–5. doi:10.1093/eurheartj/ehw504.PubMedCrossRef

Goldstein JL, Brown MS. Molecular medicine. The cholesterol quartet. Science (New York, NY). 2001;292(5520):1310–2.CrossRef

Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111(12):1795–803. doi:10.1172/jci18925.PubMedPubMedCentralCrossRef

Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63(19):1935–47. doi:10.1016/j.jacc.2014.01.060.PubMedCrossRef

10.

Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262–8. doi:10.1016/j.atherosclerosis.2012.02.019.PubMedCrossRef

11.

Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol. 2010;22(4):422–9. doi:10.1016/j.ceb.2010.05.004.PubMedPubMedCentralCrossRef

12.

Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev. 2004;25(1):49–68.PubMedPubMedCentral

13.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–90a. doi:10.1093/eurheartj/eht273.PubMedPubMedCentralCrossRef

14.

Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173(1):55–68. doi:10.1016/j.atherosclerosis.2003.11.010.PubMedCrossRef

15.

Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl):S172–7. doi:10.1194/jlr.R800091-JLR200.PubMedPubMedCentral

16.

Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97(11):3956–64. doi:10.1210/jc.2012-1563.PubMedCrossRef

17.

•• Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi:10.1093/eurheartj/ehw272. Most recent European Dyslipidemia Guidelines PubMedCrossRef

18.

Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59. doi:10.1016/j.jacc.2013.11.005.PubMedCrossRef

19.

Catapano AL., Graham IM. ‘Ten Commandments’ from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2966. doi:10.1093/eurheartj/ehw415.

20.

McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, et al. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART modifiable risk score. Eur Heart J. 2011;32(5):581–9. doi:10.1093/eurheartj/ehq448.PubMedCrossRef

21.

Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021–31. doi:10.1056/NEJMoa1600176.PubMedCrossRef

22.

• Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45. doi:10.1161/01.cir.0000437738.63853.7a. Most recent US Prevention Guidelines PubMedCrossRef

23.

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. doi:10.1016/S0140-6736(10)61350-5.PubMedCrossRef

24.

Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London, England). 2015;385(9976):1397–405. doi:10.1016/s0140-6736(14)61368-4.CrossRef

25.

•• Ridker PM, Mora S, Rose L, Group JTS. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37(17):1373–9. doi:10.1093/eurheartj/ehw046. This study provides interesting data on the variability of response to statin treatment.PubMedPubMedCentralCrossRef

26.

Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48–60. doi:10.1038/nrcardio.2015.124.PubMedCrossRef

27.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. doi:10.1001/jama.2009.1619.PubMedCrossRef

28.

Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579–85. doi:10.1161/circresaha.115.306398.PubMedPubMedCentralCrossRef

29.

Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet (London, England). 2012;380(9841):572–80. doi:10.1016/s0140-6736(12)60312-2.CrossRef

30.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22. doi:10.1056/NEJMoa0706628.PubMedCrossRef

31.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99. doi:10.1056/NEJMoa1206797.PubMedCrossRef

32.

Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KA, Gibson CM, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial. Am Heart J. 2015;170(6):1061–9. doi:10.1016/j.ahj.2015.09.007.PubMedCrossRef

33.

Rosenson RS, Brewer HB, Rader DJ. Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. Circ Res. 2014;114(12):1880–9. doi:10.1161/circresaha.114.302805.PubMedCrossRef

34.

Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121(7):2693–708. doi:10.1172/jci42946.PubMedPubMedCentralCrossRef

35.

Hafiane A, Jabor B, Ruel I, Ling J, Genest J. High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am J Cardiol. 2014;113(2):249–55. doi:10.1016/j.amjcard.2013.09.006.PubMedCrossRef

36.

Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–28. doi:10.1056/NEJMoa0902604.PubMedCrossRef

37.

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–9. doi:10.1001/jama.2009.801.PubMedCrossRef

38.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386(10002):1472–83. doi:10.1016/S0140-6736(15)61252-1.PubMedCrossRef

39.

Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60(8):716–21. doi:10.1016/j.jacc.2012.04.038.PubMedCrossRef

40.

Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278–88. doi:10.1016/j.jacc.2014.01.006.PubMedCrossRef

41.

Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32–41. doi:10.1056/NEJMoa1308027.PubMedCrossRef

42.

Triglyceride Coronary Disease Genetics C, Emerging Risk Factors C, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634–9. doi:10.1016/S0140-6736(10)60545-4.CrossRef

43.

Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–333. doi:10.1161/CIR.0b013e3182160726.PubMedCrossRef

44.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121–37. doi:10.1097/HJR.0b013e3283294b1d.PubMedCrossRef

45.

Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34(24):1826–33. doi:10.1093/eurheartj/ehs431.PubMedCrossRef

46.

Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–52. doi:10.1038/ng.2795.PubMedPubMedCentralCrossRef

47.

Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–36. doi:10.1016/j.jacc.2012.08.1026.PubMedCrossRef

48.

Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96(6):1737–44.PubMedCrossRef

49.

Kersten S. The genetics of dyslipidemia—when less is more. N Engl J Med. 2016;374(12):1192–3. doi:10.1056/NEJMe1601117.PubMedCrossRef

50.

Myocardial Infarction G, Investigators CAEC, Stitziel NO, Stirrups KE, Masca NG, Erdmann J, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134–44. doi:10.1056/NEJMoa1507652.CrossRef

51.

Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308. doi:10.1001/jama.298.3.299.PubMedCrossRef

52.

Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–63.PubMedCrossRef

53.

Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92(5):1189–96. doi:10.3945/ajcn.2010.29673.PubMedCrossRef

54.

Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–90. doi:10.1056/NEJMoa1200303.PubMedCrossRef

55.

Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL. AHA Science advisory: Lyon diet heart study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association step I dietary pattern on cardiovascular disease. Circulation. 2001;103(13):1823–5.PubMedCrossRef

56.

Estruch R, Ros E, Martinez-Gonzalez MA. Mediterranean diet for primary prevention of cardiovascular disease. N Engl J Med. 2013;369(7):676–7. doi:10.1056/NEJMc1306659.PubMed

57.

de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon diet heart study. Circulation. 1999;99(6):779–85.PubMedCrossRef

58.

Rivellese AA, Giacco R, Annuzzi G, De Natale C, Patti L, Di Marino L, et al. Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. Clin Nutr (Edinburgh, Scotland). 2008;27(1):133–41. doi:10.1016/j.clnu.2007.07.005.CrossRef

59.

Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320–8.PubMed

60.

Stein EA, Raal FJ. Polygenic familial hypercholesterolaemia: does it matter? Lancet. 2013;381(9874):1255–7. doi:10.1016/S0140-6736(13)60187-7.PubMedCrossRef

61.

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet (London, England). 2016;388(10059):2532–61. doi:10.1016/s0140-6736(16)31357-5.CrossRef

62.

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England). 2012;380(9841):581–90. doi:10.1016/s0140-6736(12)60367-5.CrossRef

63.

Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):Cd004816. doi:10.1002/14651858.CD004816.pub5.

64.

Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139–51. doi:10.1111/j.1365-2710.2009.01085.x.PubMedCrossRef

65.

Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59(2):239–52. doi:10.1111/j.1742-1241.2005.00461.x.PubMedCrossRef

66.

Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39–43. doi:10.1161/01.CIR.0000131517.20177.5a.PubMed

67.

Zhou Q, Liao JK. Pleiotropic effects of statins—basic research and clinical perspectives. Circ J: Off J Jpn Circ Soc. 2010;74(5):818–26.CrossRef

68.

Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943–8.PubMedCrossRef

69.

Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002;54(3):309–19.PubMedPubMedCentralCrossRef

70.

Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072–82. doi:10.1056/NEJMoa1405386.PubMedCrossRef

71.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. doi:10.1056/NEJMoa1410489.PubMedCrossRef

72.

The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251(3):365–74.

73.

The Lipid Research Clinics Program. Pre-entry characteristics of participants in the Lipid Research Clinics’ Coronary Primary Prevention Trial. J Chronic Dis. 1983;36(6):467–79.

74.

The lipid research clinics coronary primary prevention trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch Intern Med. 1992;152(7):1399–410.

75.

Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, et al. The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis. 2016;249:200–8. doi:10.1016/j.atherosclerosis.2016.03.003.PubMedCrossRef

76.

Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–84. doi:10.1016/S0140-6736(10)60656-3.PubMedCrossRef

77.

Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217(2):492–8. doi:10.1016/j.atherosclerosis.2011.04.020.PubMedCrossRef

78.

Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57(2):267–72. doi:10.1097/FJC.0b013e318202709f.PubMedCrossRef

79.

Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A):20B–6B. doi:10.1016/j.amjcard.2008.02.029.PubMedCrossRef

80.

Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245–55.PubMedCrossRef

81.

Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353–61. doi:10.1016/j.atherosclerosis.2009.12.023.PubMedCrossRef

82.

Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67. doi:10.1056/NEJMoa1107579.CrossRef

83.

Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12. doi:10.1056/NEJMoa1300955.CrossRef

84.

Benes LB, Bassi NS, Davidson MH. Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia. Vasc Health Risk Manag. 2016;12:481–90. doi:10.2147/vhrm.s58149.PubMedPubMedCentralCrossRef

85.

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–92. doi:10.1016/j.amjcard.2012.05.031.PubMedCrossRef

86.

Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5(6):808–18. doi:10.1161/CIRCOUTCOMES.112.966168.PubMedCrossRef

87.

Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6. doi:10.1038/ng1161.PubMedCrossRef

88.

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99. doi:10.1056/NEJMoa1501031.PubMedCrossRef

89.

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9. doi:10.1056/NEJMoa1500858.PubMedCrossRef

90.

Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40–51. doi:10.7326/M14-2957.PubMedCrossRef

91.

Navarese EP, Kolodziejczak M, Dimitroulis D, Wolff G, Busch HL, Devito F, et al. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. Eur Heart J Cardiovasc Pharmacother. 2016;2(1):44–53. doi:10.1093/ehjcvp/pvv045.PubMedCrossRef

92.

Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Orum H, et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One. 2010;5(5):e10682. doi:10.1371/journal.pone.0010682.PubMedPubMedCentralCrossRef

93.

Lindholm MW, Elmen J, Fisker N, Hansen HF, Persson R, Moller MR, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther: J Am Soc Gene Ther. 2012;20(2):376–81. doi:10.1038/mt.2011.260.CrossRef

94.

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51. doi:10.1056/NEJMoa1609243.PubMedCrossRef

95.

Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet (London, England). 2014;383(9911):60–8. doi:10.1016/s0140-6736(13)61914-5.CrossRef

96.

Strat AL, Ghiciuc CM, Lupusoru CE, Mitu F. New class of drugs: therapeutic RNAi inhibition of PCSK9 as a specific LDL-c lowering therapy. Rev Med Chir Soc Med Nat Iasi. 2016;120(2):228–32.PubMed

97.

Ahmad Z, Khera A. The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management. Curr Atheroscler Rep. 2015;17(1):469. doi:10.1007/s11883-014-0469-2.PubMedCrossRef

98.

Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet (London, England). 2013;381(9860):40–6. doi:10.1016/s0140-6736(12)61731-0.CrossRef

99.

Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114(16):1729–35. doi:10.1161/circulationaha.105.606442.PubMedCrossRef

100.

Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022–32. doi:10.1161/circulationaha.113.001292.PubMedCrossRef

101.

Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105(10):1413–9. doi:10.1016/j.amjcard.2010.01.003.PubMedCrossRef

102.

Tg, Hdl Working Group of the Exome Sequencing Project NHL, Blood I, Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31. doi:10.1056/NEJMoa1307095.CrossRef

103.

Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168(1):81–9.PubMedCrossRef

104.

Khetarpal SA, Qamar A, Millar JS, Rader DJ. Targeting ApoC-III to reduce coronary disease risk. Curr Atheroscler Rep. 2016;18(9):54. doi:10.1007/s11883-016-0609-y.PubMedCrossRef

105.

Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322(5908):1702–5. doi:10.1126/science.1161524.PubMedPubMedCentralCrossRef

106.

Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–35. doi:10.1056/NEJMoa1001689.PubMedPubMedCentralCrossRef

107.

Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33(7):1696–705. doi:10.1161/ATVBAHA.113.301373.PubMedPubMedCentralCrossRef

108.

Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93. doi:10.1056/NEJMoa1409065.PubMedPubMedCentralCrossRef

109.

Heller DA, de Faire U, Pedersen NL, Dahlen G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med. 1993;328(16):1150–6. doi:10.1056/nejm199304223281603.PubMedCrossRef

Titel: Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
verfasst von: Veronika Sanin
Vanessa Pfetsch
Wolfgang Koenig
Publikationsdatum: 01.07.2017
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 7/2017
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-017-0869-3

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Myocarditis: A Clinical Overview

The Contemporary Role of Stents and Angioplasty for the Treatment of Infrapopliteal Disease in Critical Limb Ischemia

Cardiovascular Risk in Survivors of Cancer

Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins